In addition to the primary treatment setting, recurrent HPV(+) tumors frequently harbor mutant/active NRF2 alleles (66); therefore, patients with recurrent HPV(+) cancer should undergo screening for NRF2 signaling if RT is to be considered as part of their treatment when other appropriate treatment options exist. The gene discussed is NFE2L2; the disease is cancer.